


## Inosine-<sup>15</sup>N<sub>4</sub>

<b>Cat. No.:</b>	HY-150792S		
<b>CAS No.:</b>	204634-01-5		
<b>Molecular Formula:</b>	C <sub>10</sub> H <sub>12</sub> <sup>15</sup> N <sub>4</sub> O <sub>5</sub>		
<b>Molecular Weight:</b>	272.2		
<b>Target:</b>	Isotope-Labeled Compounds		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 10 mg/mL (36.74 mM; Need ultrasonic and warming)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	3.6738 mL	18.3688 mL	36.7377 mL
5 mM	0.7348 mL	3.6738 mL	7.3475 mL
10 mM	0.3674 mL	1.8369 mL	3.6738 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Inosine-<sup>15</sup>N<sub>4</sub> is the <sup>15</sup>N labeled Inosine[1].

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA